A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas

Inclusion Criteria

• •1. Provision of signed and dated, written informed consent prior to any study-specific procedures, sampling, and analyses.
• •2. Aged 18 to 75 years as of the date of consent.
• •3. Histological or cytological confirmation of a solid tumor, and has relapsed or refractory from standard therapies.
• •4. Subjects with solid tumors have at least 1 measurable lesion per RECIST v1.1.
• •5. Estimated life expectancy of a minimum of 12 weeks.
• •6. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 at ICF signature.